Table 3.
Comparison of postoperative outcomes and complication rates of included patients operated for malignant colorectal neoplasm. RCS robot-assisted colorectal surgery, LCS laparoscopic colorectal surgery, CRP C-reactive protein
| Postoperative outcomes and complication rates | Level | RCS, n =143 | LCS, n = 155 | p-value |
|---|---|---|---|---|
| Length of hospital stay, median (IQR), days | 4 (4–5) | 5 (4–7) | < 0.001b | |
| Time to first flatus, median (IQR), days | 2 (1–2) | 1 (1–2) | 0.145b | |
| Time to first stool, median (IQR), days | 3 (2–3) | 2 (1–3) | 0.033b | |
| Surgical complication rate (Clavien Dindo), n (%) | I-II | 7 (4.9%) | 11 (7.1%) | 0.519a |
| III-V | 8 (5.6%) | 13 (8.4%) | ||
| Type of surgical complication rate (Clavien Dindo IV), n (%) | Postoperative bleeding | 3 (2.1%) | 4 (2.6%) | |
| Ileus | 1 (0.7%) | 2 (1.3%) | ||
| Wound abscess | 3 (2.1%) | 3 (1.9%) | ||
| Intraabdominal abscess | 0 (0%) | 1 (0.6%) | ||
| Stoma complication rate | 1 (0.7%) | 5 (3.2%) | ||
| Anastomotic leakage | 0 (0%) | 1 (0.6%) | ||
| Other | 7 (4.9%) | 8 (5.2%) | ||
| Medical complication rate (Clavien Dindo), n (%) | I-II | 18 (12.5%) | 28 (18.1%) | 0.340a |
| III-V | 6 (4.2%) | 3 (1.9%) | ||
| Type of medical complication rate (Clavien Dindo I-V), n (%) | Acute myocardial infarction | 0 (0%) | 1 (0.6%) | |
| Pneumonia | 3 (2.1%) | 8 (5.2%) | ||
| Cardiac insufficiency | 3 (2.1%) | 3 (1.9%) | ||
| Pulmonary embolism | 1 (0.7%) | 3 (1.9%) | ||
| Respiratory insufficiency | 3 (2.1%) | 5 (3.2%) | ||
| Renal insufficiency | 2 (1.4%) | 4 (2.6%) | ||
| Sepsis | 1 (0.7%) | 0 (0%) | ||
| Other | 11 (7.7%) | 7 (4.5%) | ||
| Mortality, n (%) | 3 (2.1%) | 1 (0.6%) | 0.500c | |
| CRP, median (IQR), mg/L | Day 1 | 43 (26–61) | 50 (31–81) | 0.027b |
| Day 2 | 70.5 (48–120) | 82 (46–127) | 0.133b | |
| Day 3 | 64 (40–105) | 82 (46–127) | 0.037b | |
| Day 4 | 43 (26–72.5) | 53 (34–93) | 0.017b | |
| Day 5 | 30 (19–66) | 44 (26–67) | 0.169b | |
| Day 6 | 24 (14–78) | 32 (20–62) | 0.470b | |
| Day 7 | 27 (18–54) | 35.5 (21–64) | 0.358b | |
| Leukocytes, median (IQR), 109/L | Day 1 | 11 (9–13) | 11 (9–13) | 0.781b |
| Day 2 | 11 (9–12) | 10 (8–12) | 0.928b | |
| Day 3 | 9 (7–11) | 10 (8–12) | 0.158b | |
| Day 4 | 8 (6–10) | 8 (7–11) | 0.016b | |
| Day 5 | 8 (6–11) | 9 (7–10) | 0.169b | |
| Day 6 | 8 (7–10) | 8 (6–10) | 0.557b | |
| Day 7 | 8.4 (±2.3) | 9.0 (±2.9) | 0.409b | |
aχ2-test
bWilcoxon rank sum test